In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

SBRT reduced biochemical failure and acute GU toxicity compared with HDR brachytherapy in intermediate-risk prostate cancer. Read more about the findings.

When Chris Muraithi, turned 45, he started going for regular tests to check his prostate. One of the tests performed during his visits to a medical facility is one that measures the level of ...

Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...

Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group Study AALL03N1 ...

Becker’s ASC Review sat down with Randy Whaley, director of business development for United Medical Systems, to tackle a reader’s question about what is needed for an ASC to be able to offer and ...

Rates of acute GI and GU toxicities with dose-escalated intensity modulated proton therapy (IMPT) for the treatment of node-positive prostate cancer. This is an ASCO Meeting Abstract from the 2025 ...